{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:19:23Z","timestamp":1763036363594},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":4033,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0924933800065299_abs1\" sec-type=\"other\"><jats:title>Objectives<\/jats:title><jats:p>This Schizophrenia Outcome Survey compared medical costs, psychopathology and adverse events in outpatients for 2 years following hospitalisation for an acute schizophrenic episode.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800065299_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Adults stabilised with haloperidol, olanzapine or risperidone entered this observational study \u22641 month after discharge and were assessed at baseline, 3, 6, 12, 18 and 24 months using Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), Global Assessment of Functioning and adverse events reporting.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800065299_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Among 323 patients (haloperidol 32, olanzapine 149, risperidone 142), baseline characteristics were similar in the olanzapine and risperidone groups, except for more first episodes in the risperidone group (<jats:italic>p<\/jats:italic> = 0.01). Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly). Sixty-eight percent of patients completed a 2-year follow-up. In all groups, CGI and GAF improved during the first 3 months (both <jats:italic>p<\/jats:italic> &lt; 0.0001) while BPRS deteriorated in the first year (all within group changes <jats:italic>p<\/jats:italic> &lt; 0.05, between group changes NS) before it stabilised. There were no significant differences in hospitalisations and no change in social profile. At the last visit, 66% of haloperidol (<jats:italic>p<\/jats:italic> &lt; 0.01), 35% of olanzapine (NS) and 39% (NS) of risperidone patients had \u22651 EPS; 69% (<jats:italic>p<\/jats:italic> &lt; 0.013), 40 and 44%, respectively, had \u22651 sexual problem (NS). Mean weight gain was 0.4 (NS), 2.6 (<jats:italic>p<\/jats:italic> &lt; 0.05) and 2.6 kg (<jats:italic>p<\/jats:italic> &lt; 0.05), respectively.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800065299_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>In this naturalistic study, treatment allocation might have introduced a bias in the interpretation of efficiency results, but olanzapine and risperidone caused less EPS than haloperidol during 2 years of outpatient follow-up.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.eurpsy.2008.11.002","type":"journal-article","created":{"date-parts":[[2009,1,2]],"date-time":"2009-01-02T14:42:00Z","timestamp":1230907320000},"page":"154-163","source":"Crossref","is-referenced-by-count":7,"title":["Belgian Schizophrenia Outcome Survey \u2013 Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol"],"prefix":"10.1017","volume":"24","author":[{"given":"J.","family":"Peuskens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Gillain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"De Graeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Van Vleymen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800065299_bib15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1209"},{"key":"S0924933800065299_bib14","doi-asserted-by":"publisher","DOI":"10.1080\/00926230600666378"},{"key":"S0924933800065299_bib11","unstructured":"[11] http:\/\/statbel.fgov.be"},{"key":"S0924933800065299_bib9","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000246215.49271.b8"},{"key":"S0924933800065299_bib8","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology (revised)","author":"Guy","year":"1976"},{"key":"S0924933800065299_bib7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0305"},{"key":"S0924933800065299_bib2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002028"},{"key":"S0924933800065299_bib6","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033346"},{"key":"S0924933800065299_bib23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00757.x"},{"key":"S0924933800065299_bib10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.02.007"},{"key":"S0924933800065299_bib18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1425"},{"key":"S0924933800065299_bib3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2004.11.002"},{"key":"S0924933800065299_bib13","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"S0924933800065299_bib5","first-page":"31","article-title":"A description of direct medical costs in patients with schizophrenia and initiated on haloperidol, olanzapine or risperidone","volume":"107\/4","author":"De Graeve","year":"2007","journal-title":"Acta Psychiatrica Belgica"},{"key":"S0924933800065299_bib4","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.6.553"},{"key":"S0924933800065299_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"S0924933800065299_bib12","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.5.654"},{"key":"S0924933800065299_bib1","doi-asserted-by":"publisher","DOI":"10.1080\/713847170"},{"key":"S0924933800065299_bib16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"S0924933800065299_bib19","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a006986"},{"key":"S0924933800065299_bib22","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.172.6.499"},{"key":"S0924933800065299_bib17","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000186832.41125.8a"},{"key":"S0924933800065299_bib20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38881.382755.2F"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933808016556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933808016556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800065299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T09:25:02Z","timestamp":1587115502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800065299\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0924933800065299"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2008.11.002","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}